OJVM  Vol.2 No.4 , December 2012
Anaphylatoxins: From Supposed Toxin Anaphylactics to Effective Mediators of the Early Events of Inflammation
Abstract: This review updates original data describing the experiments showing the complement origin of anaphylatoxins unexplainable submerged under the surface of the articles related to the subject. Next, recalls subsequent data describing the anaphylatoxins peptide nature and sequences, the cell receptors with which they interact and activate and the outcome of the cell responses. The review continues by highlighting the anaphylatoxin biological properties focusing on the unequivocal participation of these mediators in inflammation. The review concludes bringing data reinforcing the promising use of these peptides as molecular primers to create specific and efficient pharmacological antagonists.
Cite this paper: W. Dias da Silva, "Anaphylatoxins: From Supposed Toxin Anaphylactics to Effective Mediators of the Early Events of Inflammation," Open Journal of Veterinary Medicine, Vol. 2 No. 4, 2012, pp. 266-280. doi: 10.4236/ojvm.2012.24043.

[1]   I. Dally, S. Peat, and H. Schild, “The Release of a Histamine-Like Substance from the Lungs of Guinea Pigs during Anaphylactic Shock,” Experimental Physiology, Vol. 25, No. 1, 1935, pp. 33-59.

[2]   J. Bordet, “Gelose et Anaphylatoxine,” Comptes rendus des Seances de la Societe de Biologie, Vol. 74, 1913, p. 877.

[3]   E. Nathan, “Uber Anaphylatoxinbildund durch Inulin Zuglich ein Beitrag uber die Bedeutung des Physiukalischen Zustandes für Anaphylatoxinbildung,” Zeitschriftfür Immunit?tsforschung, Vol. 23, 1915, p. 204.

[4]   F. G. Novy and P. D. Kruif, “Anaphylatoxin and Anaphylaxis. III. Ager Anaphylatoxin: Rabbit Serum. IV. Agar Anaphylatoxin: Rat Serum,” The Journal of Infectious Diseases, Vol. 20, No. 5, 1913, pp. 499-535. doi:10.1093/infdis/20.5.499

[5]   H. H. Dale and C. H. Kelleway, “Anaphylaxis and anaphylatoxins,” Philosophical Transactions of the Royal Society, Vol. 211, No. 382-390, 1922, pp. 273-315. doi:10.1098/rstb.1923.0006

[6]   R. Bartosch, W. Feldberg and E. Nagel, “Das Freiwerden eines Histaminahnlichen Stoffes bey der Anaphylxie des Meerschweinchens,” Pfluger’s Archiv fur die Gesamte Physiologie des Menschen und der Tiere, Vol. 230, No. 1, 1932, pp. 129-153. doi:10.1007/BF01751974

[7]   H. O. Schild, “Histamine Release in Anaphylactic Shock from Various Tissues of the Guinea-Pig,” The Journal of Physiology, Vol. 95, 3, 1939, pp. 393-403.

[8]   M. R. E. Silva, O. G. Bier and M. Aronson, “Histamine Release by Anaphylaxis,” Nature, Vol. 168, 1951, pp. 465-466. doi:10.1038/168465a0

[9]   A. G. Osler, H. G. Randall, B. M. Hill and Z. Ovary, “Studies on the Mechanism of Hypersensitivity Phenomena. III. The Participation of Complement in the Formation of Anaphylatoxin,” The Journal of Experimental Medicine, Vol. 110, No. 2, 1959, pp. 311-339.

[10]   M. W. Turner and J. B. Nativig, “Nomenclature of Complement,” In: M. W. Turner and J. B. Nativig, Eds., Immunology Nomenclature, Hogrefe & Huber Publishers, Seatle, 1999, pp. 2-93.

[11]   B. F. Tack, R. A. Harrison, J. Janatova, M. L. Thomas and J. W. Prahl, “Evidence for Presence of an Internal Thiolester Bond in Third Component of Human Complement,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, No. 10, 1980, pp. 5764-8576.

[12]   J. C. Jensenius, “The Mannan-Binding Lectin (MBL) Pathway of Complement Activation: Biochemistry, Biology and Clinical Implications,” Advances in Experimental Medicine and Biology, Vol. 564, 2005, pp. 21-22. doi:10.1007/0-387-25515-X_6

[13]   M. W. Turner and R. M. Hamvas, “Mannose-Binding Lectin: Structure, Function, Genetics and Disease Associations,” Reviews in Immunogenetics, Vol. 2, No. 3, 2000, pp. 305-322.

[14]   J. K. van de Wetering, L. M. van Golde and J. J. Batenburg, “Collectins: Players of the Innate Immune System,” European Journal of Biochemistry, Vol. 271, No. 7, 2004, pp. 1229-1249. doi:10.1111/j.1432-1033.2004.04040.x

[15]   O. Ratinoff and I. H. Lepow, “Some Properties of an Esterase Derived from Preparations of the First Component of Complement,” The Journal of Experimental Medicine, Vol. 106, No. 2, 1957, pp. 327-343. doi:10.1084/jem.106.2.327

[16]   O. D. Ratinoff and I. H. Lepow, “Complement as Mediator Inflammation: Enhancement of Vascular Permeability by Purified Human C1 Esterase,” The Journal of Experimental Medicine, Vol. 118, No. 5, 1963, pp. 681-698. doi:10.1084/jem.118.5.681

[17]   R. D. Smink Jr., R. W. Abernethy, O. D. Ratnoff and I. H. Lepow, “Enhancement of Vascular Permeability by Mixtures of C’1 Esterase and Normal Serum,” Proceedings of the Society for Experimental Biology and Medicine, Vol. 116, No. 2, 1964, pp. 280-283.

[18]   W. D. Silva and H. I. Lepow, “Anaphylatoxin Formation by Purified C1 Esterase,” The Journal of Immunology, Vol. 95, 1965, pp. 1080-1089.

[19]   J. Pensky, L. R. Levy and I. H. Lepow, “Partial Purification of a Serum Inhibitor of C’1-Esterase,” The Journal of Biological Chemistry, Vol. 236, 1961, pp. 1674-1679.

[20]   A. L. Haines and I. H. Lepow, “Studies on Human C’1-Esterase. I. Purification and Enzymatic Properties,” The Journal of Immunology, Vol. 92, 1964, pp. 456-467.

[21]   I. H. Lepow, E. W. Todd, R. D. Smink and J. Pensky, “Purification of the Second Component (C2) of Human Complement,” Federation Proceedings, Vol. 24, 1965, p. 446.

[22]   H. J. Muller-Eberhard and C. E. Biro, “Isolation and Description of the Fourth Component of Human Complement,” The Journal of Experimental Medicine, Vol. 118, No. 3, 1963, pp. 447-466. doi:10.1084/jem.118.3.447

[23]   H. J. Muller-Eberhard, U. Nilsson and T. Aronsson, “Isolation and Characterization of Two Beta1-Glycoproteins of Human Serum,” The Journal of Experimental Medicine, Vol. 111, No. 2, 1960, pp. 201-215. doi:10.1084/jem.111.2.201

[24]   W. D. Silva, J. W. Eisele and I. H. Lepow, “Complement as a Mediator of Inflammation. III. Purification of the Activity with Anaphylatoxin Properties Generated by Interaction of the First Four Components of Complement and Identification as a Cleavage Product of C3,” The Journal of Experimental Medicine, Vol. 126, No. 6, 1967, p. 1027. doi:10.1084/jem.126.6.1027

[25]   W. D. Silva and H. I. Lepow, “Properties of Anaphylatoxin Prepared from Purified Components of Human Complement,” Biochemistry, Vol. 3, 1966, p. 497.

[26]   W. D. Silva and I. H. Lepow, “Complement as a Mediator of Inflammation. II. Biological Properties of Anaphylatoxin Prepared with Purified Components of Human Complement,” The Journal of Experimental Medicine, Vol. 125, No. 5, 1967, pp. 921-946.

[27]   WHO, “Nomenclature of Complement,” Bulletin of the World Health Organization, 1968, pp. 935-938.

[28]   H. J. Muller-Eberhard, M. J. Polley and M. A. Calcott, “Formation and Functional Significance of a Molecular Complex Derived from the Second and the Fourth Component of Human Complement,” The Journal of Experimental Medicine, Vol. 125, No. 2, 1967, pp. 359-380.

[29]   C. G. Cochrane and H. J. Müller-Eberhard, “Biological Effects of C3 Fragmentation,” Federation Proceedings, Vol. 26, 1967, p. 362.

[30]   J. Jensen, “Anaphylatoxin in Its Relation to the Complement System,” Science, Vol. 155, No. 3766, 1967, pp. 1122-1123.

[31]   J. P. Gorski, T. E. Hugli and H. J. Muller-Eberhard, “C4a: The Third Anaphylatoxin of the Human Complement System,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 76, No. 10, 1979, pp. 5299-5302.

[32]   H. N. Fernandez and T. E. Hugli, “Partial Characterization of Human C5a Anaphylatoxin. I. Chemical Description of the Carbohydrate and Polypeptide Prtions of Human C5a,” The Journal of Immunology, Vol. 117, No. 5, 1976, pp. 1688-1694.

[33]   T. E. Hugli, “Biochemistry and Biology of Anaphylatoxins,” Complement, Vol. 3, No. 3, 1986, 111-127.

[34]   T. E. Hugli, “Chemical Aspects of the Serum Anaphylatoxins,” Contemporary Topics in Molecular Immunology, Vol. 7, 1978, pp. 181-214.

[35]   T. E. Hugli, F. Marceau and C. Lundberg, “Effects of Complement Fragments on Pulmonary and Vascular Smooth Muscle,” The American Review of Respiratory Disease, Vol. 135, No. 6, 1987, pp. S9-S13.

[36]   A. R. Johnson, T. E. Hugli and H. J. Muller-Eberhard, “Release of Histamine from Rat Mast Cells by the Complement Peptides C3a and C5a,” Immunology, Vol. 28, No. 6, 1975, pp. 1067-1080.

[37]   P. J. Jose, M. J. Forrest and T. J. Williams, “Human C5a des Arg Increases Vascular Permeability,” The Journal of Immunology, Vol. 127, No. 6, 1981, pp. 2376-2380.

[38]   D. E. Chenoweth and M. G. Goodman, “The C5a Receptor of Neutrophils and Macrophages,” Agents and Actions Supplement, Vol. 12, 1983, pp. 252-273.

[39]   D. E. Chenoweth and T. E. Hugli, “Human C5a and C5a Analogs as Probes of the Neutrophil C5a Receptor,” Molecular Immunology Journal, Vol. 17, No. 2, 1980, pp. 151-161.

[40]   M. S. Hausman, R. Snyderman and S. E. Mergenhagen, “Humoral Mediators of Chemotaxis of Mononuclear Leukocytes,” The Journal of Infectious Diseases, Vol. 125, No. 6, 1972, pp. 595-602.

[41]   C. Gerard and T. E. Hugli, “Identification of Classical Anaphylatoxin as the Des-Arg form of the C5a Molecule: Evidence of a Modulator Role for the Oligosaccharide Unit in Human Des-Arg74-C5a,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 78, No. 3, 1981, pp. 1833-1837.

[42]   N. P. Gerard and C. Gerard, “The Chemotactic Receptor for Human C5a Anaphylatoxin,” Nature, Vol. 349, No. 6310, 1991, pp. 614-617.

[43]   N. P. Gerard, M. K. Hodges, J. M. Drazen, P. F. Weller and C. Gerard, “Characterization of a Receptor for C5a Anaphylatoxin on Human Eosinophils,” The Journal of Biological Chemistry, Vol. 264, No. 3, 1989, pp. 1760-1766.

[44]   H. N. Fernandez, P. M. Henson, A. Otani and T. E. Hugli, “Chemotactic Response to Human C3a and C5a Anaphylatoxins. I. Evaluation of C3a and C5a Leukotaxis in Vitro and Under Stimulated in Vivo Conditions,” The Journal of Immunology, Vol. 120, No. 1, 1978, pp. 109-115.

[45]   R. A. Wetsel, “Expression of the Complement C5a Anaphylatoxin Receptor (C5aR) on Non-Myeloid Cells,” Immunology Letters, Vol. 44, No. 2-3, 1995, pp. 183-187.

[46]   M. P. Williamson and V. S. Madison, “Three-Dimensional Structure of Porcine C5adesArg from 1H Nuclear Magnetic Resonance Data,” Biochemistry, Vol. 29, No. 12, 1990, pp. 2895-2905.

[47]   D. F. Carney and T. E. Hugli, “Interaction of the N-Terminal Region of Human C5a with the Neutrophil C5a Receptor,” Protein Science, Vol. 2, 1993, pp. 1391-1399. doi:10.1002/pro.5560020904

[48]   E. R. Zuiderweg, D. G. Nettesheim, K. W. Mollison and G. W. Carter, “Tertiary Structure of Human Complement Component C5a in Solution From Nuclear Magnetic Resonance Data,” Biochemistry, Vol. 28, No. 1, 1989, 172-185.

[49]   T. E. Hugli, W. T. Morgan and H. J. Muller-Eberhard, “Circular Dichroism of C3a Anaphylatoxin. Effects of pH, Heat, Guanidinium Chloride, and Mercaptoethanol on Conformation and Function,” The Journal of Biological Chemistry, Vol. 250, No. 4, 1975, pp. 1479-1483.

[50]   V. A. Bokisch and H. J. Muller-Eberhard, “Anaphylatoxin Inactivator of Human Plasma: Its Isolation and Characterization as a Carboxypeptidase,” Journal of Clinical Investigation, Vol. 49, No. 12, 1970, pp. 2427-2436.

[51]   E. W. Mathews, S. L. Mueller-Ortiz and R. A. Wetsel, “Carboxypeptidases Pleiotropic Regulator of Inflammation,” Molecular Immunology, Vol. 40, No. 11, 2004, pp. 785-793.

[52]   S. Sayah, A. C. Jauneau, C. Patte, M. C. Tonon, H. Vaudry and M. Fontaine, “Two Different Transduction Pathways Are Activated by C3a and C5a Anaphylatoxins on Astrocytes,” Brain Research. Molecular Brain Research, Vol. 112, No. 1-2, 2003, pp. 53-60.

[53]   N. Tuteja, “Signaling through G Protein Coupled Receptors,” Plant Signaling and Behavior, Vol. 4, No. 10, 2009, pp. 942-947.

[54]   J. Yan, V. Mihaylov, X. Xu, J. A. Brzostowski, H. Li, L. Liu, T. D. Veenstra, C. A. Parent and T. Jin, “A Gbetagamma Effector, ElmoE, transduces GPCR Signaling to the Actin Network During Chemotaxis,” Developmental Cell, Vol. 22, No. 1, 2012, pp. 92-103.

[55]   P. J. Daffern, P. H. Pfeifer, J. A. Ember and T. E. Hugli, “C3a Is a Chemotaxin for Human Eosinophils but Not for Neutrophils. I. C3a Stimulation of Neutrophils Is Secondary to Eosinophil Activation,” The Journal of Experimental Medicine, Vol. 181, No. 6, 1995, pp. 2119-2127.

[56]   M. M. Glovsky, T. E. Hugli, T. Ishizaka, L. M. Lichtenstein and B. W. Erickson, “Anaphylatoxin-Induced Histamine Release with Human Leukocytes: Studies of C3a Leukocyte Binding and Histamine Release,” Journal of Clinical Investigation, Vol. 64, No. 3, 1979, pp. 804-811.

[57]   R. Gutzmer, M. Lisewski, J. Zwirner, S. Mommert, C. Diesel, M. Wittmann, A. Kapp and T. Werfel, “Human Monocyte-Derived Dendritic Cells Are Chemoattracted to C3a after Up-Regulation of the C3a Receptor with Interferons,” Immunology, Vol. 111, No. 4, 2004, pp. 435-443.

[58]   A. Klos, S. Bank, C. Gietz, W. Bautsch, J. Kohl, M. Burg and T. Kretzschmar, “C3a Receptor on dibutyryl-cAMP-Differentiated U937 Cells and Human Neutrophils: The Human C3a Receptor Characterized by Functional Responses and 125I-C3a Binding,” Biochemistry, Vol. 31, No. 46, 1992, pp. 11274-11282.

[59]   J. Zwirner, O. Gotze, A. Sieber, A. Kapp, G. Begemann, T. Zuberbier and T. Werfel, “The Human Mast Cell Line HMC-1 Binds and Responds to C3a but Not C3a(desArg),” Scandinavian Journal of Immunology, Vol. 47, No. 1, 1998, pp. 19-24.

[60]   J. Zwirner, T. Werfel, H. C. Wilken, E. Theile and O. Gotze, “Anaphylatoxin C3a but Not C3a(desArg) Is a Chemotaxin for the Mouse Macrophage Cell Line J774,” European Journal of Immunology, Vol. 28, No. 5, 1998, pp. 1570-1577.

[61]   P. Gasque, S. K. Singhrao, J. W. Neal, P. Wang, S. Sayah, M. Fontaine and B. P. Morgan, “The Receptor for Complement Anaphylatoxin C3a Is Expressed by Myeloid Cells and Nonmyeloid Cells in Inflamed Human Central Nervous System: Analysis in Multiple Sclerosis and Bacterial Meningitis,” The Journal of Immunology, Vol. 160, No. 7, 1998, pp. 3543-3554.

[62]   A. Ischenko, S. Sayah, C. Patte, S. Andreev, P. Gasque, M. T. Schouft, H. Vaudry and M. Fontaine, “Expression of a Functional Anaphylatoxin C3a Receptor by Astrocytes,” Journal of Neurochemistry, Vol. 71, No. 6, 1998, pp. 2487-2496.

[63]   T. Monsinjon, P. Gasque, P. Chan, A. Ischenko, J. J. Brady and M. C. Fontaine, “Regulation by Complement C3a and C5a Anaphylatoxins of Cytokine Production in Human Umbilical Vein Endothelial Cells,” The FASEB Journal, Vol. 17, No. 9, 2003, pp. 1003-1014.

[64]   L. Fregonese, F. J. Swan, A. van Schadewijk, M. Dolhnikoff, M. A. Santos, M. R. Daha, J. Stolk, T. Tschernig, P. J. Sterk, P. S. Hiemstra, K. F. Rabe and T. Mauad, “Expression of the Anaphylatoxin Receptors C3aR and C5aR Is Increased in Fatal Asthma,” Journal of Allergy and Clinical Immunology, Vol. 115, No. 6, 2005, pp. 1148-1154.

[65]   T. Werfel, K. Kirchhoff, M. Wittmann, G. Begemann, A. Kapp, F. Heidenreich, O. Gotze and J. Zwirner, “Activated Human T Lymphocytes Express a Functional C3a Receptor,” The Journal of Immunology, Vol. 165, No. 11, 2000, pp. 6599-6605.

[66]   R. S. Ames, Y. Li, H. M. Sarau, P. Nuthulaganti, J. J. Foley, C. Ellis, Z. Zeng, K. Su, A. J. Jurewicz, R. P. Hertzberg, D. J. Bergsma and C. Kumar, “Molecular Cloning and Characterization of the Human Anaphylatoxin C3a Receptor,” The Journal of Biological Chemistry, Vol. 271, No. 34, 1996, pp. 20231-20234.

[67]   T. Crass, R. S. Ames, H. M. Sarau, M. A. Tornetta, J. J. Foley, J. Kohl, A. Klos and W. Bautsch, “Chimeric Receptors of the Human C3a Receptor and C5a Receptor (CD88),” The Journal of Biological Chemistry, Vol. 274, No. 13, 1999, pp. 8367-8370.

[68]   J. Gao, H. Choe, D. Bota, P. L. Wright, C. Gerard and N. P. Gerard, “Sulfation of Tyrosine 174 in the Human C3a Receptor Is Essential for Binding of C3a Anaphylatoxin,” The Journal of Biological Chemistry, Vol. 278, No. 39, 2003, pp. 37902-37908.

[69]   R. B. Penn, A. N. Pronin and J. L. Benovic, “Regulation of G Protein-Coupled Receptor Kinases,” Trends in Cardiovascular Medicine Journal, Vol. 10, No. 2, 2000, pp. 81-89.

[70]   I. U. Schraufstatter, K. Trieu, L. Sikora, P. Sriramarao and R. DiScipio, “Complement C3a and C5a Induce Different Signal Transduction Cascades in Endothelial Cells,” The Journal of Immunology, Vol. 169, No. 4, 2002, pp. 2102-2110.

[71]   P. Langkabel, J. Zwirner and M. Oppermann, “Ligand- Induced Phosphorylation of Anaphylatoxin Receptors C3aR and C5aR Is Mediated by G Protein-Coupled Receptor Kinases,” European Journal of Immunology, Vol. 29, No. 9, 1999, pp. 3035-3046.

[72]   R. T. Venkatesha, E. Berla Thangam, A. K. Zaidi and H. Ali, “Distinct Regulation of C3a-Induced MCP-1/CCL2 and Rantes/CCL5 Production in Human Mast Cells by Extracellular Signal Regulated Kinase and PI3 Kinase,” Molecular Immunology Journal, Vol. 42, No. 5, 2005, pp. 581-587.

[73]   J. A. Ember and T. E. Hugli, “Complement Factors and Their Receptors,” Immunopharmacology, Vol. 38, No. 1-2, 1997, p. 3. doi:10.1016/S0162-3109(97)00088-X

[74]   D. E. Chenoweth and T. E. Hugli, “Demonstration of Specific C5a Receptor on Intact Human Polymorphonuclear Leukocytes,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 75, No. 8, 1978, pp. 3943-3947.

[75]   A. Morelli, A. Larregina, I. Chuluyan, E. Kolkowski and L. Fainboim, “Expression and Modulation of C5a Receptor (CD88) on Skin Dendritic Cells. Chemotactic Effect of C5a on Skin Migratory Dendritic Cells,” Immunology, Vol. 89, No. 1, 1996, pp. 126-134.

[76]   T. Werfel, M. Oppermann, G. Begemann, O. Gotze and J. Zwirner, “C5a Receptors Are Detectable on Mast Cells in Normal Human Skin and in Psoriatic Plaques but Not in Weal and Flare Reactions or in Uticaria Pigmentosa by Immunohistochemistry,” Archives of Dermatological Research, Vol. 289, No. 2, 1997, pp. 83-86.

[77]   S. Nataf, N. Davoust, R. S. Ames and S. R. Barnum, “Human T Cells Express the C5a Receptor and Are Chemoattracted to C5a,” The Journal of Immunology, Vol. 162, No. 7, 1999, pp. 4018-4023.

[78]   S. Nataf, P. F. Stahel, N. Davoust and S. R. Barnum, “Complement Anaphylatoxin Receptors on Neurons: New Tricks for Old Receptors?” Trends in Neurosciences, Vol. 22, No. 9, 1999, pp. 397-402.

[79]   M. A. Connelly, R. A. Moulton, A. K. Smith, D. R. Lindsey, M. Sinha, R. A. Wetsel and C. Jagannath, “Mycobacteria-Primed Macrophages and Dendritic Cells Induce an Up-Regulation of Complement C5a Anaphylatoxin Receptor (CD88) in CD3+ Murine T Cells,” Journal of Leukocyte Biology, Vol. 81, No. 1, 2007, pp. 212-220.

[80]   M. G. Strainic, J. Liu, D. Huang, F. An, P. N. Lalli, N. Muqim, V. S. Shapiro, G. R. Dubyak, P. S. Heeger and M. E. Medof, “Locally Produced Complement Fragments C5a and C3a Provide both Costimulatory and Survival Signals to Naive CD4+ T Cells,” Immunity, Vol. 28, No. 3, 2008, pp. 425-435.

[81]   P. N. Lalli, M. G. Strainic, M. Yang, F. Lin, M. E. Medof and P. S. Heeger, “Locally Produced C5a Binds to T Cell-Expressed C5aR to Enhance Effector T-Cell Expansion by Limiting Antigen-Induced Apoptosis,” Blood, Vol. 112, No. 5, 2008, pp. 1759-1766.

[82]   D. E. van Epps and D. E. Chenoweth, “Analysis of the Binding of Fluorescent C5a and C3a to Human Peripheral Blood Leukocytes,” The Journal of Immunology, Vol. 132, No. 6, 1984.

[83]   A. Soruri, S. Kim, Z. Kiafard and J. Zwirner, “Characterization of C5aR Expression on Murine Myeloid and Lymphoid Cells by the Use of a Novel Monoclonal Antibody,” Immunology Letters, Vol. 88, No. 1, 2003, pp. 47-52.

[84]   D. A. Copland, K. Hussain, S. Baalasubramanian, T. R. Hughes, B. P. Morgan, H. Xu, A. D. Dick and L. B. Nicholson, “Systemic and Local Anti-C5 Therapy Reduces the Disease Severity in Experimental Autoimmune Uveoretinitis,” Clinical & Experimental Immunology, Vol. 159, No. 3, 2010, pp. 303-314.

[85]   H. Wei, Z. Lin, J. Feng, H. Peng, R. Guo, G. Han, S. Geng, X. Lang, Y. Sun, B. Shen and Y. Li, “Identification of Conformational Core Epitope Lys(6)(8) in C5a Based on the 3-D Modeling Complex C5a and Its Functional Antibody F20,” Molecular Immunology Journal, Vol. 48, No. 12-13, 2011, pp. 1377-1383.

[86]   R. S. Ames, D. Lee, J. J. Foley, A. J. Jurewicz, M. A. Tornetta, W. Bautsch, B. Settmacher, A. Klos, K. F. Erhard, R. D. Cousins, A. C. Sulpizio, J. P. Hieble, G. McCafferty, K. W. Ward, J. L. Adams, W. E. Bondinell, D. C. Underwood, R. R. Osborn, A. M. Badger and H. M. Sarau, “Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models,” The Journal of Immunology, Vol. 166, No. 10, 2001, pp. 6341-6348.

[87]   R. G. DiScipio, P. J. Daffern, M. A. Jagels, D. H. Broide and P. Sriramarao, “A Comparison of C3a and C5a-Mediated Stable Adhesion of Rolling Eosinophils in Postcapillary Venules and Transendothelial Migration in Vitro and in Vivo,” The Journal of Immunology, Vol. 162, No. 2, 1999, pp. 1127-1136.

[88]   S. Takafuji, K. Tadokoro, K. Ito and C. A. Dahinden, “Degranulation from Human Eosinophils Stimulated with C3a and C5a,” International Archives of Allergy and Immunology, Vol. 104, Suppl. 1, 1994, pp. 27-29.

[89]   W. H. Fischer and T. E. Hugli, “Regulation of B Cell Functions by C3a and C3a(desArg): Suppression of TNF-Alpha, IL-6 and the Polyclonal Immune Response,” The Journal of Immunology, Vol. 159, No. 9, 1997, pp. 4279-4286.

[90]   W. H. Fischer, M. A. Jagels and T. E. Hugli, “Regulation of IL-6 Synthesis in Human Peripheral Blood Mononuclear Cells by C3a and C3a(desArg),” The Journal of Immunology, Vol. 162, 1, 1999, pp. 453-459.

[91]   Y. Fukuoka and T. E. Hugli, “Demonstration of a Specific C3a Receptor on Guinea Pig Platelets,” The Journal of Immunology, Vol. 140, No. 10, 1988, pp. 3496-3501.

[92]   A. A. Humbles, B. Lu, C. A. Nilsson, C. Lilly, E. Israel, Y. Fujiwara, N. P. Gerard and C. Gerard, “A Role for the C3a Anaphylatoxin Receptor in the Effector Phase of Asthma,” Nature, Vol. 406, No. 6799, 2000, pp. 998-1001.

[93]   M. Noris and G. Remuzzi, “Hemolytic Uremic Syndrome,” Journal of the American Society of Nephrology, Vol. 16, 2005, pp. 1035-1050. doi:10.1681/ASN.2004100861

[94]   J. Scheiring, S. P. Andreoli and L. B. Zimmerhackl, “Treatment and Outcome of Shiga-Toxin-Associated Hemolytic Uremic Syndrome (HUS),” Pediatric Nephrology, Vol. 23, No. 10, 2008, pp. 1749-1760.

[95]   P. I. Tarr, C. A. Gordon and W. L. Chandler, “Shiga-Toxin-Producing Escherichia Coli and Haemolytic Uraemic Syndrome,” Lancet, Vol. 365, No. 9464, 2005, pp. 1073-1086.

[96]   C. W. Strey, M. Markiewski, D. Mastellos, R. Tudoran, L. A. Spruce, L. E. Greenbaum and J. D. Lambris, “The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration,” The Journal of Experimental Medicine, Vol. 198, No. 6, 2003, pp. 913-923.

[97]   G. Moxley and S. Ruddy, “Elevated Plasma C3 Anaphylatoxin Levels in Rheumatoid Arthritis Patients,” Arthritis & Rheumatism, Vol. 30, No. 10, 1987, pp. 1097-1104.